Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

AAV

Treating Krabbe disease with FBX-101 1:58
Treating Krabbe disease with FBX-101
John Maslowski • 27 Jan 2022
Overcoming immunogenicity of gene therapies 1:16
Overcoming immunogenicity of gene therapies
Timothy Miller • 18 Nov 2021
RESKUE: AAV-based gene therapy for Krabbe disease 0:59
RESKUE: AAV-based gene therapy for Krabbe disease
Timothy Miller • 18 Nov 2021
Increasing manufacturing capabilities for gene therapies 1:58
Increasing manufacturing capabilities for gene therapies
Timothy Miller • 18 Nov 2021
Treating Krabbe disease with AAV-based gene therapies 2:07
Treating Krabbe disease with AAV-based gene therapies
Timothy Miller • 18 Nov 2021
The future of gene therapies for the eye 1:27
The future of gene therapies for the eye
Sue Washer • 22 Oct 2021
Manufacturing challenges in the advanced therapies sector 2:29
Manufacturing challenges in the advanced therapies sector
Sue Washer • 22 Oct 2021
Immunogenicity of AAV-based gene therapies 3:50
Immunogenicity of AAV-based gene therapies
Paul Gissen • 6 Oct 2021
AAV-based gene therapy for X-linked retinitis pigmentosa 2:03
AAV-based gene therapy for X-linked retinitis pigmentosa
Sue Washer • 22 Oct 2021
Optogenetics in advanced retinitis pigmentosa 1:52
Optogenetics in advanced retinitis pigmentosa
Sue Washer • 22 Oct 2021
Treating achromatopsia with AAV-based gene therapy 2:12
Treating achromatopsia with AAV-based gene therapy
Sue Washer • 22 Oct 2021
Enhancing AAV gene therapy in children with inborn errors of metabolism 2:25
Enhancing AAV gene therapy in children with inborn errors of metabolism
Gloria Gonzalez-Aseguinolaza • 18 May 2021
The need for next-gen AAV vectors 1:14
The need for next-gen AAV vectors
Arun Srivastava • 17 May 2021
Synthetic AAV vectors for gene therapy of hemophilia in children 4:15
Synthetic AAV vectors for gene therapy of hemophilia in children
Arun Srivastava • 18 May 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy